MedTrace Logo

Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back

NCT00783965 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2016-02-11

Study results available
· View outcomes & findings →

Summary

RATIONALE: Drugs used in chemotherapy, such as tazarotene, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This randomized phase II trial is comparing two different schedules of topical tazarotene and topical placebo to see how well they work in treating patients with basal cell skin cancer and basal cell nevus syndrome on the chest.

Conditions

  • Skin Carcinoma

Interventions

DRUG

tazarotene

Applied to the skin

OTHER

placebo

Applied to the skin

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • UCSF Benioff Children's Hospital Oakland

    lead OTHER

Principal Investigators

  • Ervin Epstein, MD · UCSF Benioff Children's Hospital Oakland

  • David R. Bickers, MD · Herbert Irving Comprehensive Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31
Primary Completion
2012-06-30
Completion
2014-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00783965 on ClinicalTrials.gov